Organization | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Shanghai China (2015)

Organization Overview

First Clinical Trial

2015

NCT03919240

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Active Ingredients

Drugs in Phase 3 Trials (4)

ciltacabtagene autoleucel (Carvykti) (2 trials)

clarithromycin (biaxin) (1 trial)

dexamethasone (1 trial)

lenalidomide (revlimid) (1 trial)

Drugs in Phase 2 Trials (7)

autologous cd19/cd22 chimeric antigen receptor t-cells (3 trials)

car-t targeted cd19/cd20/cd22/cd30 (1 trial)

cd19 car-t cells (6 trials)

cyclophosphamide (cytoxan) (3 trials)

fludarabine (fludara) (2 trials)

humanized cd19 car-t cells with crs suppression technology (1 trial)

tislelizumab (1 trial)

Drugs in Phase 1 Trials (3)

autologous t cells (1 trial)

sscart-19 cells (1 trial)

u87 car-t (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Leukemia (Phase 2)

Leukemia, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Multiple Myeloma (Phase 3)

Neoplasms, Plasma Cell (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 16
# of Trial APIs: 14